The following SMART 100 profile and the information it contains is a duplication of content submitted by the applicant during the entry process. As a function of entry, applicants were required to declare that all details are factually correct, do not infringe on another’s intellectual property and are not unlawful, threatening, defamatory, invasive of privacy, obscene, or otherwise objectionable. Some profiles have been edited for reasons of space and clarity. More about the SMART 100.
This innovation initially came to life when…
Dr. Peter Cooper and Dr. Nikolai Petrovsky met at a social function in Canberra and realised that they shared a common interest in research into improved vaccines. From this initial research collaboration, Advax, a novel plant-sugar-based ingredient that enhances vaccine action, was born. Advax is now a leading ingredient in vaccines being developed in Australia, the US and Japan against pandemic influenza, HIV, malaria and a range of other infectious diseases.
WHAT & HOW
The purpose of this innovation is to…
Advax™ is a paradigm changer being the first product to increase vaccine potency while minimizing vaccine side effects. Advax™ has enabled breakthroughs in vaccines against pandemic influenza, hepatitis, SARS, Japanese encephalitis, shigella, malaria and Ebola, amongst many others.
It does this by…
Advax™ enhances the ability of the human immune system to recognise and respond to a vaccine, thereby resulting in stronger and longer-lasting protection against the relevant infection.
PURPOSE & BENEFITS
This innovation improves on what came before because…
For the last 90 years, a critical ingredient at the heart of most vaccines has been an aluminium compound known as alum. Advax™ is a natural plant-based successor to alum that is not only a better immune enhancer than alum but is also safer and better tolerated.
Its various benefits to the customer/end-user include…
Consumers around the world stand to benefit from safer, more effective and better tolerated vaccines through use of Advax™ to replace outdated aluminium vaccine adjuvants.
COMPETITIVE LANDSCAPE
In the past, this problem was solved by…
For the last 90 years, most vaccines have contained aluminium salts as a necessary ingredient to make them effective. Advax™ provides one of the first opportunities to replace outdated aluminium vaccine adjuvants with an alternative made from a natural plant sugar.
It’s predecessors/competitors include…
Since the 1920s, aluminium salts have exclusively been used in vaccine manufacture. Advax™ represents one of the first major breakthroughs in vaccine adjuvants in almost a hundred years.
TARGET MARKET
It is made for…
Several billion doses of vaccine containing aluminium adjuvant are sold each year. Our aim is to ultimately see Advax™ as a safer and more effective ingredient replace aluminium in every one of these billions of vaccine doses used each year.
DISTRIBUTION STRATEGY
It is available for sale through…
Advax™ as a key vaccine ingredient is provided by Vaxine to global vaccine manufacturers to incorporate into their vaccines in place of aluminium adjuvants.
Our marketing strategy is to…
Vaxine has signed an $8.5 million vaccine development contract with the US Department of Health and has licensed its Advax™ technology to one of Japan’s largest vaccine manufacturers for use in production of their next generation pandemic influenza vaccine. Vaxine is also currently in licensing negotiations with a range of other human and veterinary vaccine manufacturers.
SUPPORTING IMAGES AND/OR VIDEO
SHOW YOUR SUPPORT FOR THIS INNOVATION
While the judging is now officially over, you can still show your support for this innovation in one of the following three ways:
- Hit the VOTE UP button: Top left of each page (Not available for IE users)
- Trigger a Reaction: Re-Tweet, Like on Facebook, etc.
- Leave a Comment: Share the love!
To check out the Anthill SMART 100 Readers’ Choice winner for 2010, click here.
